Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.45 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GALR2 | O43603 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | CCR6 | P51684 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6200886 | 0.94 | SLC9A1 (0.62) | SLC9A1NPSR1MAPTPDE7ACXCR2 | |
| SCHEMBL6167927 | 0.88 | MAPT (0.50) | SLC9A1NPSR1MAPTPDE7AHTT | |
| SCHEMBL8611539 | 0.87 | SLC9A1 (0.64) | SLC9A1NPSR1MAPTPDE7ACXCR2 | |
| SCHEMBL6354726 | 0.86 | SLC9A1 (0.59) | SLC9A1NPSR1MAPTPDE7ACXCR2 | |
| SCHEMBL3251790 | 0.86 | NPSR1 (0.50) | SLC9A1NPSR1MAPTPDE7AHTT | |
| SCHEMBL30748250 | 0.86 | NPSR1 (0.50) | SLC9A1NPSR1MAPTPDE7AHTT | |
| SCHEMBL6816581 | 0.83 | CXCR2 (0.63) | SLC9A1NPSR1MAPTPDE7ACXCR2 | |
| SCHEMBL2972082 | 0.83 | SLC9A1 (0.60) | SLC9A1NPSR1MAPTPDE7ACXCR2 | |
| SCHEMBL29386167 | 0.83 | SLC9A1 (0.63) | SLC9A1NPSR1MAPTPDE7ACXCR2 | |
| SCHEMBL10759973 | 0.83 | SLC9A1 (0.63) | SLC9A1NPSR1MAPTPDE7ACXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702021-A1 | COMPOUNDS CAPABLE OF MODULATING GPR65 | Pathios Therapeutics Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| WO-2024224064-A1 | COMPOUNDS CAPABLE OF MODULATING GPR65 | Pathios Therapeutics Limited (GB) | 2024-10-31 | — | — | WO | disclosed |
| EP-4419203-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118451080-A | Tricyclic GPR65 modulators | 帕蒂奥斯治疗有限公司 | 2024-08-06 | — | — | CN | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | GPR65, GPR3, NR1H2 | SLC9A1 2093/4885NPSR1 168/4885MAPT 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.